A Phase I/II Trial of AK112 in Advanced Solid Tumor
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 59
- 试验地点
- 1
- 主要终点
- Number of participants with adverse events (AEs)
研究概览
简要总结
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with advanced solid tumor malignancies. This trial is a two parts, phase I/II study. All patients are advanced solid tumor, Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Part one is dose escalation phase,part two is dose expansion phase. The primary end point is safety. Secondary end points are objective response rate,progression-free survival and overall survival per RECIST1.1.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Aged 18 to 75 years old (at the time consent is obtained);
- •Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures);
- •Have histologically- or cytologically-confirmed diagnosis of advanced solid tumor;
- •Available archived tumor tissue sample to allow for correlative biomarker studies. In the setting where archival material is unavailable or unsuitable for use, the subject must consent and undergo fresh tumor biopsy;
- •Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 or
- •Subject must have at least one measurable lesion according to RECIST Version1.1;
- •Adequate organ function;
- •Females of childbearing potential and non-sterilized males who are sexually active must use an effective method;
- •Adequate life expectancy.
排除标准
- •History of severe hypersensitivity reactions to other mAbs;
- •Unresolved toxicities from prior anticancer therapy, defined as having not resolved to NCI CTCAE v5.0 Grade 0 or 1, or to levels dictated in the inclusion/exclusion criteria;
- •Major surgical procedure within 30 days prior to the first dose of AK112 or still recovering from prior surgery;
- •Receipt of any immunotherapy, any conventional or investigational systemic anticancer therapy within 4 weeks prior to the first dose of AK112 except for treatment with small-molecule tyrosine kinase-targeted agents within 2 weeks prior to the first dose of AK112;
- •History of primary immunodeficiency;
- •Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis);
- •History of organ transplant or hematopoietic stem cell that requires use of immunosuppressives;
- •Known allergy or reaction to any component of the AK112 formulation;
- •History of interstitial lung disease or non-infectious pneumonitis except for those induced by radiation therapies;
- •Known history of tuberculosis;
- •Known history of HIV;
- •Receipt of live attenuated vaccination within 30 days prior to the first dose of AK112;
- •Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
研究组 & 干预措施
1
AK112
干预措施: AK112 (Drug)
结局指标
主要结局
Number of participants with adverse events (AEs)
时间窗: From time ICF is signed until 90 days after last dose of AK112
An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product. temporally associated with the use of study treatment, whether or not considered related to the study treatment
Number of participants with DLTs
时间窗: During the first four weeks of treatment
DLTs will be assessed during the first 4 weeks of treatment for dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria, and assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle (4 weeks) of treatment.
次要结局
- Objective response rate (ORR)(Up to 2 years)
- Progression-free survival (PFS)(Up to 2 years)
- Disease control rate (DCR)(Up to 2 years)
- Overall survival (OS)(Up to 2 years)